| Price controls prevent drug companies from even having a chance to profit, thus destroying the incentive to invest. Developing a new prescription drug is an extremely risky endeavor, typically taking up to 15 years and $2.6 billion. The failure rate is extremely high; about 9-in-10 experimental drugs that enter clinical trials never receive regulatory approval. Investors are only willing to fund this risky research because they might profit if a drug is successful. Artificially capping drug prices would also discourage research and the development of tomorrow’s miracle drugs. |
You are here:
You are here:
You are here:
You are here:
You are here:
You are here:
You are here:
You are here:
You are here:
You are here:
You are here:
You are here: